Johnson D H, Cunha B A
Infectious Disease Division, Winthrop-University Hospital, Mineola, New York, USA.
Med Clin North Am. 1995 Jul;79(4):733-43. doi: 10.1016/s0025-7125(16)30036-0.
Aztreonam is a monocyclic beta-lactam antibiotic that is active exclusively against the aerobic gram-negative bacilli. It is not ototoxic or nephrotoxic and so is used as an alternative to aminoglycosides in a variety of clinical situations. In polymicrobial infections or when used for empiric therapy, aztreonam must be combined with other antimicrobial agents active against gram-positive and anaerobic species. Aztreonam is often effective against resistant strains of gram-negative organisms, which are often involved in nosocomial infections. Overuse of aztreonam should be avoided to prevent the emergence of resistant P. aeruginosa strains. Except in the treatment of P. aeruginosa infections, aztreonam should not be added to beta-lactam regimens for additional gram-negative coverage.
氨曲南是一种单环β-内酰胺类抗生素,仅对需氧革兰氏阴性杆菌有活性。它没有耳毒性或肾毒性,因此在多种临床情况下用作氨基糖苷类药物的替代品。在混合感染或用于经验性治疗时,氨曲南必须与其他对革兰氏阳性菌和厌氧菌有效的抗菌药物联合使用。氨曲南通常对革兰氏阴性菌的耐药菌株有效,这些菌株常与医院感染有关。应避免过度使用氨曲南以防止耐药铜绿假单胞菌菌株的出现。除治疗铜绿假单胞菌感染外,氨曲南不应添加到β-内酰胺类治疗方案中以增加对革兰氏阴性菌的覆盖范围。